17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
Positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis (RMS) have been released by Swiss pharma giant Roche. 17 May 2023
New late-stage data from the FLAURA2 trial confirm the treatment potential for Tagrisso (osimertinib), while underscoring the value of targeted therapies for certain kinds of lung cancer. 17 May 2023
Much has been made of the sudden rise in sales of Wegovy (semaglutide) and the weight loss drug’s impact in driving rapid growth at Novo Nordisk. 16 May 2023
Dermavant Sciences, an immuno-dermatology-focused subsidiary of Switzerland-based Roivant Sciences, today announced positive results from ADORING 1, the second of two double-blind, randomized, vehicle-controlled Phase III studies to evaluate the efficacy and safety of topical Vtama (tapinarof) cream. 16 May 2023
The European Federation of Pharmaceutical Industries and Associations (EFPIA) is preparing to publish an update on variable rates of access to new medicines in the region. 15 May 2023
The US Food and Drug Administration on Friday finally approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. 15 May 2023
The executive director of ARPharM, the Bulgarina pharma trade group, delivered the "Evolution of Access to Health in Bulgaria over the last decade" presentation at the ISPOR Bulgaria chapter and ISPOR CEE Chapter 11th Adriatic Congress on Pharmacoeconomics and Outcomes Research with Focus on CEE in Sofia. 15 May 2023
A team of German Institute for Quality and Efficiency in Health Care (IQWiG) authors, together with Rita Banzi from the Italian Mario Negri Institute, analyzed the effects of the lack of evidence on orphan drugs at the European and national level. The conclusion is that the need for reform is great. 15 May 2023
New real-world data for the newly-approved schizophrenia medicine Uzedy (risperidone) have been presented at the annual meeting of the Schizophrenia International Research Society (SIRS). 15 May 2023
UK pharma major GSK saw its shares gain 2.3% to 1,478 pence today, after it presented preliminary positive results from the Phase III trial evaluating the immunological vaccine effectiveness and safety of its MenABCWY combination vaccine candidate, administered as two doses given six months apart in healthy individuals aged 10-25 years. 12 May 2023
Following a regulatory update, Japanese speciality pharma company Kyowa Kirin has announced it will pull the plug on its small molecule bardoxolone methyl. 12 May 2023
The US Food and Drug Administration (FDA) yesterday announced it is requiring sponsors of amphetamine and methylphenidate products, a class of stimulant medications used to treat attention deficit/hyperactivity disorder (ADHD) and other disorders, to update and standardize their prescribing information to clearly inform patients, caregivers and health care professionals of risks associated with their medications. 12 May 2023
The Russian government will consider the allocation up to 48 billion roubles ($625 million) in public procurements of anti-HIV drugs this year, The Pharma Letter’s local correspondent reports. 12 May 2023
The Indian vaccine market has carved a niche for itself at the global level and is anticipated to reach a valuation of $3.07 billion by 2025, according to Minister of State for Science and Technology Jitendra Singh, who was on an official visit to the UK. 12 May 2023
Shares of Denmark’s Zealand Pharma were up more than 10% at 243.00 kroner today after, along with German partner Boehringer Ingelheim, it announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose. 11 May 2023
German life sciences company Bayer was trading 7% lower in mid-afternoon trading on Thursday after presenting its first-quarter financial results and latest outlook for 2023 as a whole. 11 May 2023
Germany’s Merck KGaA took in 5.3 billion euros ($5.8 billion) in the first quarter, a little short of many analysts’ expectations, a 1.8% increase from the same period of 2022. 11 May 2023
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.